Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients.
COVID-19
SARS-CoV-2
epidemiology
hemodialysis
mortality
renal dialysis
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
19
11
2021
revised:
01
07
2022
accepted:
05
07
2022
pubmed:
26
7
2022
medline:
26
7
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic is a global public health problem. Patients with end-stage renal disease on hemodialysis are at a higher risk of infection and mortality than the general population. Worldwide, a vaccination campaign has been developed that has been shown to reduce severe infections and deaths in the general population. However, there are currently limited data on the clinical efficacy of vaccinations in the hemodialysis population. A national multicenter observational cohort was performed in Chile to evaluate the clinical efficacy of anti-SARS-CoV-2 vaccination in end-stage renal disease patients on chronic hemodialysis from February 2021 to August 2021. In addition, the BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines were evaluated. The efficacy of vaccination in preventing SARS-CoV-2 infection, hospitalizations, and deaths associated with COVID-19 was determined. A total of 12,301 patients were evaluated; 10,615 (86.3%) received a complete vaccination (2 doses), 490 (4.0%) received incomplete vaccination, and 1196 (9.7%) were not vaccinated. During follow-up, 1362 (11.0%) patients developed COVID-19, and 150 died (case fatality rate: 11.0%). The efficacy of the complete vaccination in preventing infection was 18.1% (95% confidence interval [CI]:11.8-23.8%), and prevention of death was 66.0% (95% CI:60.6-70.7%). When comparing both vaccines, BNT162b2 and CoronaVac were effective in reducing infection and deaths associated with COVID-19. Nevertheless, the BNT162b2 vaccine had higher efficacy in preventing infection (42.6% vs. 15.0%) and deaths (90.4% vs. 64.8%) compared to CoronaVac. The results of our study suggest that vaccination against SARS-CoV-2 in patients on chronic hemodialysis was effective in preventing infection and death associated with COVID-19.
Identifiants
pubmed: 35874643
doi: 10.1016/j.ekir.2022.07.007
pii: S2468-0249(22)01505-4
pmc: PMC9287586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2176-2185Informations de copyright
© 2022 International Society of Nephrology. Published by Elsevier Inc.
Références
Kidney360. 2021 Jul 13;2(9):1491-1498
pubmed: 35373105
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Kidney Int. 2021 Oct;100(4):928-936
pubmed: 34284044
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
Kidney Int. 2021 Jun;99(6):1470-1477
pubmed: 33774082
EClinicalMedicine. 2021 Nov;41:101143
pubmed: 34608454
Kidney Int. 2021 Sep;100(3):702-704
pubmed: 34216675
Kidney Int. 2020 Dec;98(6):1530-1539
pubmed: 32810523
Metabol Open. 2021 Dec;12:100124
pubmed: 34541483
Am J Kidney Dis. 2021 May;77(5):748-756.e1
pubmed: 33465417
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Kidney Int Rep. 2021 May;6(5):1429-1432
pubmed: 33748552
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Rev Med Chil. 2020 May;148(5):711-712
pubmed: 33399769
JAMA Netw Open. 2021 Feb 1;4(2):e2037640
pubmed: 33606033
J Nephrol. 2021 Oct;34(5):1387-1403
pubmed: 34417996
Clin Kidney J. 2021 Mar 09;14(7):1835-1844
pubmed: 34211708
Int J Biol Sci. 2020 Mar 15;16(10):1753-1766
pubmed: 32226295